An observational study in Neuroendocrine Tumor, Carcinoid and Neuroendocrine Carcinoma, sponsored by Wren Laboratories LLC. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by Wren Laboratories LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 219 studies in Neuroendocrine Tumors with a site in United States — 45 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.
Among the 219 studies in Neuroendocrine Tumors with a site in United States, this one is the 9th largest by planned enrollment of the 24 observational ones that give a count, is one of 13 that started in 2015, is one of 24 observational ones, reaches primary completion later than 1 of the 75 other live ones, and was the 74th registered.
544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →45 of the 219 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Washington University School of Medicine · Sites in United States
Ages 18+
Compass Therapeutics · Sites in United States
Ages 18+
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in United States, Brazil, France and 6 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
219 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 72 · Phase 2 111 · Phase 3 18 · Phase 4 5
First in 2001; this study’s year is marked. 13 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 134 across 130 observational studies indexed under Neuroendocrine Tumors.
Median enrollment 35 across the 190 interventional studies, 203 across the 24 observational. Of the 126 that completed or were terminated, 70 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 219 have an industry lead sponsor. The 10 most frequent:
Wren Laboratories LLC is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Wren Laboratories LLC has 2 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
28 of the studies in Neuroendocrine Tumors with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT06881992Phase 3RezoluteA Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | 2027-09 |
| NCT05263050Fox Chase Cancer CenterTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 219 studies in Neuroendocrine Tumors with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems. Treatment options include surgery, medical and ablative therapies as well as peptide-receptor radionuclide therapy. Survival is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. One challenge is to develop accurate non-invasive blood tests that can detect neuroendocrine tumor activity. A second challenge is to evaluate the effectiveness of molecular biomarkers in the natural history of this disease. RegisterNET registry aims at collecting data and blood samples from patients presenting with a NET. Data will be entered prospectively and anonymized after informed consent. All physicians who treat neuroendocrine tumor patients are invited to participate to the registry through prospective agreements and sub-study protocols with Wren Laboratories. Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types and grades of tumors, treatment modalities and patient outcomes (e.g. disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.
Background: Survival for neuroendocrine tumors is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. Non-invasive biomarkers have been identified that can improve diagnosis and prognosis of patients. Little, however, is known about the utility of these markers in clinical practice.
Objective: To systematically and prospectively collect clinical information and blood samples for NETest from neuroendocrine tumors to evaluate the clinical validity of this biomarker for diagnosis, surveillance, and prediction of disease prognosis and response to targeted therapeutics.
Methods: All neuroendocrine tumors (gastroenteropancreatic and pulmonary) are following informed consent. Data will be entered prospectively and anonymized. Patient history including a quality of life survey are completed by contributing physicians and blood sample is collected for analysis. All information will be transferred to the database. Evaluation of treatment modalities and patient outcomes (e.g. disease recurrence) will be assessed at follow-up times.
The primary objectives of the project are to:
The secondary objectives of the project include:
Analyses will include:
Patients with a histologically confirmed diagnosis of a neuroendocrine tumor undergoing treatment and follow-up evaluation. This includes real-world patients as well as patients included in investigator-initiated clinical studies (IICS) e.g., PRRT or curative surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-invasive blood test
Also known as: Multianalyte Algorithm Analysis of circulating neuroendocrine tumor transcripts
Tumor-related recurrence or progression
Image-based identification of recurrent or progressive tumor disease
Time frame: 5 years
Tumor-related diagnosis
Histological confirmation of neuroendocrine tumor
Time frame: 1 year
Tumor-related mortality
Survival from disease
Time frame: 10 years
Quality of Life Evaluation
Questionnaire to evaluate quality of life status
Time frame: 5 years
Biomarker prediction of treatment response and disease relapse
Biomarker prediction of treatment response and disease relapse. This involves measurements of changes in NETest levels between two time-points. Changes can be in actual values or be evaluated as % change. Alterations in blood measurements can be correlated with survival curves (PFS and/or OS).
Time frame: 10 years
Plan to share: Yes — De-identififed, anonymized information including changes in NETest and outcomes e.g., PFS.
The record gives a start of Feb 2015, a primary completion of Mar 2018 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wren Laboratories LLC